Effect of Azithromycin on Failure Proportion of Severe Periodontitis Non-surgical Treatment

NCT ID: NCT04198649

Last Updated: 2024-08-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-11-02

Study Completion Date

2023-11-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Primary purpose: Evaluate the effect of azithromycin on failure proportion of severe chronic periodontitis non-surgical treatment; failure characterized by the persistence of at least one periodontal pocket\> 5mm at 6 months

Secondary purpose:

* Evaluate the effect of azithromycin on the persistence of pathological periodontal pockets \> 5mm during non-surgical treatment of severe chronic periodontitis at 3 months and 6 months
* Evaluate the effect of azithromycin on the changes of clinical signs, periopathogen levels, expression of macrolides resistance genes, and expression of antimicrobial peptides (PAMs) during treatment of severe chronic periodontitis at 3 months and 6 months
* Assess therapeutic observance and side effects of antibiotic treatment
* Assess at 3 and 6 months the potential interactions of local, bacterial (periopathogen and resistance gene) clinical factors, and host defense (PAMs) with the effect of azithromycin, on failure proportion of severe chronic periodontitis non-surgical treatment

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Severe Chronic Periodontitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Azithromycin

62 patients Non-surgical periodontal treatment and two 250mg azithromycin tablets one time daily for 3 days

Group Type EXPERIMENTAL

Non-surgical periodontal treatment and azithromycin treatment

Intervention Type DRUG

Procedure: periodontal treatment: oral hygiene instruction, scaling and root planning Drug: two 250mg azithromycin tablets one time daily for 3 days after scaling and root planning sessions

Placebo

62 patients Non-surgical periodontal treatment and two 250mg starch tablets one time daily for 3 days

Group Type PLACEBO_COMPARATOR

Non-surgical periodontal treatment and placebo treatment

Intervention Type OTHER

Procedure: periodontal treatment: oral hygiene instruction, scaling and root planning Placebo: two 250mg starch tablets one time daily for 3 days after scaling and root planning sessions

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Non-surgical periodontal treatment and azithromycin treatment

Procedure: periodontal treatment: oral hygiene instruction, scaling and root planning Drug: two 250mg azithromycin tablets one time daily for 3 days after scaling and root planning sessions

Intervention Type DRUG

Non-surgical periodontal treatment and placebo treatment

Procedure: periodontal treatment: oral hygiene instruction, scaling and root planning Placebo: two 250mg starch tablets one time daily for 3 days after scaling and root planning sessions

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with severe generalized chronic periodontitis (loss of attachment ≥ 5mm at \> 30% sites) (AAP classification 1999) and periodontal pockets \>5mm on at least 5% of sites
* presence of bleeding on probing (≥ 30%)
* male or female subject older than 35 Years
* patient with at least 15 teeth including at least 2 molars (excluding wisdom teeth)
* patient with social assurance
* voluntary patient who signed informed consent

Exclusion Criteria

* Patient with contraindications to treatment with azithromycin or its excipient: absolute contraindications are the history of allergy to macrolides or one of the excipients used in this study, association with ergot derivatives Rye, Cisapride, colchicine, and severe hepatic deficiencies. Other contraindications are for patients at risk of cardiac arrhythmia (diagnosis of QT interval prolongation and/or concomitant treatments, electrolytic disorder (hypokalemia, hypomagnesemia, cardiac arrhythmia, heart failure), severe renal failure, and drug associations (Antivitamin K, statins)
* Patient with aggressive periodontitis (AAP classification 1999)
* Patient smoking more than 10 cigarettes/day
* Patient with endocarditis risk or requiring antibiotic prophylaxis
* Patient with antibiotic treatment within 6 months prior to periodontal examination
* Patient with anti-inflammatory treatment in the month preceding periodontal examination and/or anti-inflammatory treatment of more than 3 consecutive days in the 3 months preceding periodontal examination
* Patient following or having followed a drug treatment (cyclosporine and other anti-rejection drugs, antiepileptic, calcium inhibitor) influencing periodontal status
* Patient with pathologies influencing periodontal status and/or systemic or local inflammatory response, such as diabetes, infectious stomatitis or not, diseases inflammatory and autoimmune, immuno-depression
* Patient with prolonged oral hygiene disability (physical/psychic impossibility of brushing teeth)
* Patient with impaired oral condition (untreated cavities, non-dental teeth rehabilitated), dental infections whose management requires antibiotic treatment within 6 months
* Patient having specialized periodontal treatment, root planning, or a periodontal surgical treatment in the year prior to the examination
* Pregnant woman or breastfeeding
* Patient with repeated chronic infections (more than 3 times per year) requiring antibiotic treatment
* Patient who had oral antiseptic treatment in the previous month
* Patient included in another intervention research protocol or in periods of exclusion (participation in an observational study remains possible)
* Patient with high bleeding risk and/or INR \> 4.
* Patient under guardianship and under protection of justice
* Patient unable to cooperate or understand the instructions related to the study and care
Minimum Eligible Age

35 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Strasbourg, France

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Les Hôpitaux Universitaires de Strasbourg

Strasbourg, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

6996

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.